DMEMEDS shared post via Reuters: U.S. FDA panel reviews Baxter immune therapy's long-term safety

Washington (Reuters) - Advisors to the U.S. Food and Drug Administration will meet on Thursday to discuss the relative risks and benefits of Baxter International Inc's experimental treatment for certain hereditary disorders of the immune system. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/4uTUEOoo9Cw/story01.htm

Read More